No change in side effects or glycemic markers with metformin/prebiotic
±, bowel movements, composite gastrointestinal symptoms, diabetes
DIABETES
Youth participants (n=6) were 67% male and aged 17.2 ± 1.7 years with a mean baseline BMI of 42 ± 9 kg/m2, HbA1c 6.4 ± 0.6%, and were within 5 years of diagnosis of diabetes (Demographic and metabolic characteristics of participants.At baseline, youth had bowel movements every 1-2 days and soft-form stool. There were no differences in stool frequency, consistency, or composite GI symptom scores between one week Phase 1 metformin/prebiotic, Phase 1 metformin/placebo, or one month Phase 2 metformin/prebiotic (Comparison of stool frequency, consistency, and composite gastrointestinal symptoms. There were no differences in Glycemic and metabolic variables during the mixed meal tolerance test and continuous glucose monitoring are shown in 